Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home

@article{Mahase2021Covid19US,
  title={Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home},
  author={Elisabeth Mahase},
  journal={BMJ},
  year={2021},
  volume={375}
}
The interim phase III trial results were released though a press release. This said that 7.3% of patients (28 of 385) who received molnupiravir and 14.1% of patients taking placebo (53 of 377) either were admitted to hospital or had died by day 29 after randomisation. At day 29 no deaths were reported in the molnupiravir group, while eight were reported in the placebo group. Recruitment to the trial was then stopped on the advice of the independent data monitoring committee because of… 
2 Citations
Covid-19: UK becomes first country to authorise antiviral molnupiravir
TLDR
Recruitment to the trial was stopped on the advice of the independent data monitoring committee because of the positive results, a release said.
What happened to our national emergency stockpiles?
When the pandemic began, many nations’ emergency stockpiles came into the spotlight—and were found wanting. Twenty months later, JaneFeinmann asks what happened, and if procurement has got any better

References

SHOWING 1-4 OF 4 REFERENCES
Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds
The anti-HIV drug lopinavir-ritonavir does not improve survival of patients with covid-19 in hospital, according to new findings from the UK RECOVERY trial. Announcing the results, which are yet to
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
TLDR
The proportional reduction in the risk of hospitalisation or death is impressive, but it is important to remember that the absolute risks were 14% reduced to 7%, so quite a lot of people need to be treated to prevent one hospitalization or death.
Covid-19: UK launches antivirals taskforce to deliver home treatments by autumn
Can the UK vaccine taskforce’s success in delivering safe and effective covid vaccines be repeated with new antiviral drugs? Elisabeth Mahase looks at the research pipeline